Development and evaluation of lipid nanoparticle-based mRNA vaccine formulations
International Journal of Multidisciplinary Trends · 01.08.2026 · 8 (8) · 13-20
DOI: 10.22271/multi.2026.v8.i8a.1148 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Multidisciplinary Trends, online erschienen am 01.08.2026. Verfasst von Mahalaxmi Dash und 3 weiteren Autor:innen.
Abstract (Originalsprache)
We developed and evaluated an optimized lipid nanoparticle (LNP)-based mRNA vaccine platform to address the critical challenges of efficient intracellular delivery, protection from degradation, and robust immune activation. The study applied a comprehensive experimental workflow, performing in vitro assays in HEK293 and dendritic cells and preclinical immunogenicity and safety assessments in BALB/c mice. Synthetic mRNA encoding the target antigen was generated by in vitro transcription, and LNPs were prepared via microfluidic mixing with a lipid composition of 50% ionizable lipid, 10% DSPC, 38.5% cholesterol, and 1.5% PEG-lipid. The optimized formulations showed a particle size of 82.4 nm, a polydispersity index of 0.16, and an encapsulation efficiency of 96.4%. In vitro, the LNP-mRNA vaccine achieved 95.2% cellular uptake, 93.8% transfection efficiency, and 96.4% cell viability with only 4.3% cytotoxicity. Immunogenicity studies indicated that the vaccine elicited a 98.2% IgG antibody response, a 95.6% neutralizing antibody response, and robust T-cell activation, with 93.1% CD4⁺ and 92.5% CD8⁺ responses, thereby markedly surpassing naked mRNA formulations (p < 0.05). Stability evaluations indicated that encapsulation efficiency stayed above 92% under refrigeration for one month, and safety assessments showed hemolysis below 2% without any observed liver or kidney toxicity. This work chiefly shows that a carefully optimized LNP composition can achieve high encapsulation efficiency, strong immunogenicity, and a favorable safety profile all at once. These findings underscore the significance of LNP delivery systems as a safe and effective platform for next-generation mRNA vaccines, with potential applications in infectious disease prevention and therapeutic vaccine development.
Zitieren
APA
Dash, M., Gupta, A., Dash, A., & Anusha, T. (2026). Development and evaluation of lipid nanoparticle-based mRNA vaccine formulations. International Journal of Multidisciplinary Trends, 8(8), 13-20. https://doi.org/10.22271/multi.2026.v8.i8a.1148
Vancouver
Dash M, Gupta A, Dash A, Anusha T. Development and evaluation of lipid nanoparticle-based mRNA vaccine formulations. International Journal of Multidisciplinary Trends. 2026;8(8):13-20. doi:10.22271/multi.2026.v8.i8a.1148
BibTeX
@article{Dash2026,
author = {Dash, Mahalaxmi and Gupta, Ayush and Dash, Ankita and Anusha, T},
title = {Development and evaluation of lipid nanoparticle-based mRNA vaccine formulations},
journal = {International Journal of Multidisciplinary Trends},
year = {2026},
volume = {8},
number = {8},
pages = {13--20},
doi = {10.22271/multi.2026.v8.i8a.1148}
}
EUVIMED